3. An antigen binding protein as claimed in claim in any preceding claim for treatment of a disease wherein the antigen binding protein is to be administered to patients at a single dose between about 35 to about 45 mg at a four to eight weekly interval.

4. An antigen binding protein as claimed in claim 3 wherein the antigen binding protein is to be administered to patients subcutaneously as a single 40 mg dose no more than once every four weeks.

5. An antigen binding protein as claimed in claim 3 or claim 4wherein the antigen binding protein is to be administered to patients subcutaneously as a single 40 mg dose no more than once every eight weeks.

6. An antigen binding protein as claimed in any one of claims 1 to 5 wherein the half-life of the antigen binding protein is increased 2 fold, 3 fold, 4 fold or 5 fold as compared to the native IgG.

7. An antigen binding protein as claimed in any preceding claim wherein administration of the antigen binding protein no more than once every four weeks in patients achieves the mean steady-state trough concentration in the patient population of between about 4 µg/ml to about 7 µg/ml.

8. An antigen binding protein as claimed in claim 7 wherein the mean steady-state trough concentration is between about 5 µg/ml to about 6 µg/ml.

9. An antigen binding protein as claimed in any one of claims 1 to 8 wherein the clearance of the antigen binding protein is about 2.ml/ hr to about 4ml/hr

10. An antigen binding protein as claimed in any preceding claim comprising a constant domain as shown in SEQ ID No: 7

11. An antigen binding protein as claimed in any one of claims 1 to 10 wherein the antigen binding protein is an antibody.

12. An antigen binding protein as claimed in any one of claims 1 to 11 wherein the antigen binding protein is to be administered with methotrexate, preferably wherein the antigen binding protein is to be administered for the treatment of rheumatoid arthritis.

13. An antigen binding protein as claimed in any one of claims 1 to 12 comprising the heavy chain sequence as shown in SEQ ID NO 5 optionally with a light chain sequence as shown in SEQ ID No: 2.

14. Use of an antigen binding protein as claimed in any preceding claim in the manufacture of a medicament for treating a patient with ~~a disease~~ rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease or Psoriasis.

15. The use of claim 14, wherein the antigen binding protein is to be administered to the patient subcutaneously as a single of dose about 35 to about 45 mg at a four to eight weekly interval.

~~16. Use of an antigen binding protein as claimed in any one of claims 1 to 15 for use in the manufacture of a medicament for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease or Psoriasis.~~

~~17~~ 15. An antigen binding protein as claimed in any one of claims 1 to 13 for use in the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease or Psoriasis.

~~18~~16. A nucleic acid comprising a nucleotide sequences encoding the antigen binding protein as claimed in any one of claims 1 to 13.

~~19~~17. A host cell comprising the nucleic acid as claimed in claim ~~18~~16.